Tianjin Jianke Biopharma

Tianjin Jianke Biopharma is a clinical-stage biotechnology company based in Tianjin, China, specializing in the development of next-generation recombinant protein therapeutics. The company leverages its proprietary super-long-acting technology platform to extend the half-life and improve the therapeutic profile of cytokines and other protein drugs. Its lead candidate, JK-001, is a long-acting interferon alpha-2b currently being evaluated in Phase 2 clinical trials for the treatment of chronic viral hepatitis. Additionally, the company is advancing a pipeline of long-acting interleukins and growth factors targeting oncology and hematology indications. Tianjin Jianke Biopharma aims to provide more convenient and effective treatment options for patients with chronic and life-threatening diseases.